NASDAQ:PAHC

Phibro Animal Health Competitors

$24.27
-0.02 (-0.08 %)
(As of 04/14/2021 03:28 PM ET)
Add
Compare
Today's Range
$24.08
Now: $24.27
$24.66
50-Day Range
$20.85
MA: $23.94
$25.23
52-Week Range
$16.27
Now: $24.27
$28.51
Volume4,569 shs
Average Volume142,779 shs
Market Capitalization$981.79 million
P/E Ratio22.90
Dividend Yield1.96%
Beta0.46

Competitors

Phibro Animal Health (NASDAQ:PAHC) Vs. EBS, TPTX, AGIO, IMAB, LEGN, and NKTR

Should you be buying PAHC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Phibro Animal Health, including Emergent BioSolutions (EBS), Turning Point Therapeutics (TPTX), Agios Pharmaceuticals (AGIO), I-Mab (IMAB), Legend Biotech (LEGN), and Nektar Therapeutics (NKTR).

Emergent BioSolutions (NYSE:EBS) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Emergent BioSolutions has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Emergent BioSolutions and Phibro Animal Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.59$54.50 million$2.9125.63
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Emergent BioSolutions has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Emergent BioSolutions and Phibro Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Phibro Animal Health11001.50

Emergent BioSolutions currently has a consensus price target of $113.6667, suggesting a potential upside of 52.94%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, equities analysts clearly believe Emergent BioSolutions is more favorable than Phibro Animal Health.

Profitability

This table compares Emergent BioSolutions and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Phibro Animal Health5.37%23.70%5.99%

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Emergent BioSolutions beats Phibro Animal Health on 13 of the 14 factors compared between the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Turning Point Therapeutics and Phibro Animal Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-25.43
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Phibro Animal Health has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Turning Point Therapeutics and Phibro Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Turning Point Therapeutics00703.00
Phibro Animal Health11001.50

Turning Point Therapeutics currently has a consensus price target of $153.7143, suggesting a potential upside of 102.82%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Turning Point Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Turning Point Therapeutics is more favorable than Phibro Animal Health.

Profitability

This table compares Turning Point Therapeutics and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Turning Point TherapeuticsN/A-23.81%-23.08%
Phibro Animal Health5.37%23.70%5.99%

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Phibro Animal Health beats Turning Point Therapeutics on 8 of the 13 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider and Institutional Ownership

92.9% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Agios Pharmaceuticals and Phibro Animal Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$117.91 million31.67$-411,470,000.00($6.86)-7.82
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Phibro Animal Health has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agios Pharmaceuticals and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agios Pharmaceuticals-170.65%-57.63%-37.15%
Phibro Animal Health5.37%23.70%5.99%

Analyst Recommendations

This is a summary of current recommendations and price targets for Agios Pharmaceuticals and Phibro Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agios Pharmaceuticals03702.70
Phibro Animal Health11001.50

Agios Pharmaceuticals currently has a consensus price target of $64.6364, suggesting a potential upside of 19.50%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Agios Pharmaceuticals is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares I-Mab and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million925.63$-208,560,000.00($28.90)-1.92
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Phibro Animal Health has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares I-Mab and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Phibro Animal Health5.37%23.70%5.99%

Analyst Ratings

This is a breakdown of current ratings and target prices for I-Mab and Phibro Animal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
Phibro Animal Health11001.50

I-Mab currently has a consensus price target of $70.00, suggesting a potential upside of 26.13%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given I-Mab's stronger consensus rating and higher probable upside, research analysts plainly believe I-Mab is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats I-Mab on 9 of the 13 factors compared between the two stocks.

Legend Biotech (NASDAQ:LEGN) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

18.9% of Legend Biotech shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Legend Biotech and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$64.39 million54.86$-132,970,000.00N/AN/A
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Phibro Animal Health has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Legend Biotech and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Legend Biotech-543.73%-205.60%-43.03%
Phibro Animal Health5.37%23.70%5.99%

Analyst Ratings

This is a breakdown of current ratings and target prices for Legend Biotech and Phibro Animal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Legend Biotech00303.00
Phibro Animal Health11001.50

Legend Biotech currently has a consensus price target of $50.6667, suggesting a potential upside of 87.93%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Legend Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Legend Biotech is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Legend Biotech on 7 of the 11 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Nektar Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Nektar Therapeutics and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million30.55$-440,670,000.00($2.52)-7.62
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.47

Phibro Animal Health has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nektar Therapeutics and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-269.05%-30.74%-22.63%
Phibro Animal Health5.37%23.70%5.99%

Analyst Ratings

This is a breakdown of current ratings and target prices for Nektar Therapeutics and Phibro Animal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics16102.00
Phibro Animal Health11001.50

Nektar Therapeutics currently has a consensus price target of $25.2857, suggesting a potential upside of 30.34%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Nektar Therapeutics is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.


Phibro Animal Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.59-2.5%$3.88 billion$1.11 billion23.98Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$76.03-1.6%$3.66 billionN/A-21.66Analyst Report
News Coverage
Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.65-3.0%$3.62 billion$117.91 million-10.88Gap Down
I-Mab logo
IMAB
I-Mab
1.2$55.45-10.5%$3.57 billion$4.31 million-1.92Increase in Short Interest
Gap Down
LEGN
Legend Biotech
1.2$26.76-1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.21-2.7%$3.41 billion$114.62 million-7.75Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.00-6.1%$3.40 billionN/A-6.06News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90-1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.26-3.1%$3.30 billion$339.08 million-12.36Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.60-0.9%$3.29 billion$36.13 million-71.04Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.13-4.4%$3.27 billion$136.47 million-12.74
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.66-3.6%$3.13 billion$26.52 million-7.90
Alkermes logo
ALKS
Alkermes
1.2$19.26-2.1%$3.00 billion$1.17 billion-41.87
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.00-4.3%$3.00 billionN/A-57.71Gap Down
Arvinas logo
ARVN
Arvinas
1.5$63.54-3.5%$3.00 billion$42.98 million-24.82News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.05-1.1%$2.99 billion$421.03 million24.31Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.61-1.1%$2.94 billion$80.43 million107.67Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.69-1.8%$2.77 billion$644.77 million-10.51
OPKO Health logo
OPK
OPKO Health
1.9$4.20-1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$22.03-4.2%$2.70 billion$260.98 million-367.17
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.00-3.1%$2.61 billion$306.49 million25.84
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$44.25-4.9%$2.60 billionN/A-24.31
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.47-4.4%$2.51 billion$60,000.00-10.08
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$46.30-6.2%$2.50 billion$25 million-9.26
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.56-3.3%$2.50 billion$2.11 million-9.00Analyst Report
News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.02-7.1%$2.46 billion$182.24 million-8.71Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.17-2.8%$2.44 billion$120.28 million-152.70Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$51.89-0.8%$2.38 billion$33.94 million-89.47
Xencor logo
XNCR
Xencor
1.0$42.96-6.4%$2.33 billion$156.70 million-30.69News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.31-2.6%$2.30 billion$15 million-17.44Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.78-4.5%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.76-0.6%$2.20 billion$963.01 million13.59News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$28.03-4.3%$2.05 billion$23.90 million-17.41Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.15-1.4%$2.00 billion$429.76 million-102.98News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.32-1.9%$1.98 billion$410,000.00-6.16Analyst Report
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.79-3.9%$1.93 billionN/A-20.00
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.96-0.2%$1.92 billion$34.51 million-17.91
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.92-2.6%$1.91 billionN/A-27.20Increase in Short Interest
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$46.85-2.5%$1.87 billionN/A0.00Analyst Report
Gap Down
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.86-5.5%$1.87 billion$103.54 million-19.44Insider Selling
MORF
Morphic
1.3$56.18-2.6%$1.87 billion$16.98 million-36.01Insider Selling
Decrease in Short Interest
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.39-4.8%$1.85 billionN/A-10.97
Kura Oncology logo
KURA
Kura Oncology
1.6$29.11-5.5%$1.82 billionN/A-17.86Gap Down
FibroGen logo
FGEN
FibroGen
1.8$19.28-2.3%$1.81 billion$256.58 million-7.39Analyst Report
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$31.27-5.4%$1.77 billion$64.19 million-9.99Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.97-0.1%$1.77 billion$14.87 million-14.17Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.83-1.2%$1.73 billion$1.63 billion14.22Analyst Report
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.28-1.5%$1.71 billion$26.87 million-12.71Insider Selling
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.